Abstract:A single dynamic PET acquisition using multiple tracers administered closely in time could provide valuable complementary information about a tumor’s status under quasiconstant conditions. This study aimed to investigate the utility of dual-tracer dynamic PET imaging with 18F-alfatide II (18F-AlF-NOTA-E[PEG4-c(RGDfk)]2) and 18F-FDG for parametric monitoring of tumor responses to therapy. Methods: We administered doxorubicin to one group of athymic nude mice with U87MG tumors and paclitaxel protein-bound particles to another group of mice with MDA-MB-435 tumors. To monitor therapeutic responses, we performed dual-tracer dynamic imaging, in sessions that lasted 90 min, starting with injection via the tail vein catheters with 18F-alfatide II, followed 40 min later by 18F-FDG. To achieve signal separation of the 2 tracers, we fit a 3-compartment reversible model to the time–activity curve of 18F-alfatide II for the 40 min before 18F-FDG injection and then extrapolated to 90 min. The 18F-FDG tumor time–activity curve was isolated from the 90-min dual-tracer tumor time–activity curve by subtracting the fitted 18F-alfatide II tumor time–activity curve. With separated tumor time–activity curves, the 18F-alfatide II binding potential (Bp = k3/k4) and volume of distribution (VD) and 18F-FDG influx rate ((K1 × k3)/(k2 + k3)) based on the Patlak method were calculated to validate the signal recovery in a comparison with 60-min single-tracer imaging and to monitor therapeutic response. Results: The transport and binding rate parameters K1–k3 of 18F-alfatide II, calculated from the first 40 min of the dual-tracer dynamic scan, as well as Bp and VD correlated well with the parameters from the 60-min single-tracer scan (R2 > 0.95). Compared with the results of single-tracer PET imaging, 18F-FDG tumor uptake and influx were recovered well from dual-tracer imaging. On doxorubicin treatment, whereas no significant changes in static tracer uptake values of 18F-alfatide II or 18F-FDG were observed, both 18F-alfatide II Bp and 18F-FDG influx from kinetic analysis in tumors showed significant decreases. For therapy of MDA-MB-435 tumors with paclitaxel protein-bound particles, a significant decrease was observed only with 18F-alfatide II Bp value from kinetic analysis but not 18F-FDG influx. Conclusion: The parameters fitted with compartmental modeling from the dual-tracer dynamic imaging are consistent with those from single-tracer imaging, substantiating the feasibility of this methodology. Even though no significant differences in tumor size were found until 5 d after doxorubicin treatment started, at day 3 there were already substantial differences in 18F-alfatide II Bp and 18F-FDG influx rate. Dual-tracer imaging can measure 18F-alfatide II Bp value and 18F-FDG influx simultaneously to evaluate tumor angiogenesis and metabolism. Such changes are known to precede anatomic changes, and thus parametric imaging may offer the promise of early prediction of therapy response.

Monitoring Anti-Angiogenic Therapy Response in Mouse U87MG Tumor Model Using 18F-FLT and 18F-FDG Micropet/ct

Early monitoring antiangiogenesis treatment response of Sunitinib in U87MG Tumor Xenograft by (18)F-FLT MicroPET/CT imaging.

Noninvasive Apoptosis Detection by F-18-Ml10 Micropet/Ct Imaging for Early Monitoring Cancer Anti-Angiogenic Therapy Response

Early Monitoring Antiangiogenesis Treatment Response of Sunitinib in U87MG Tumor Xenograft By18f-Flt MicroPET/CT Imaging

Alteration of Hypoxia and Glucose Metabolism Measured by 18F-Fmiso and 18F-Fdg Micropet/Ct Imaging During Anti-Angiogenic Therapy

Optimization of Early Response Monitoring and Prediction of Cancer Antiangiogenesis Therapy Via Noninvasive Pet Molecular Imaging Strategies of Multifactorial Bioparameters

Monitoring Response To Gefitinib In Nude Mouse Tumor Xenografts By F-18-Fdg Micropet-Ct: Correlation Between F-18-Fdg Uptake And Pathological Response

Apoptosis Imaging with 18F-Ml-10 Micropet/Ct for Early Prediction of Response to Treatment in A Human Pancreatic Tumor Xenograft Model

Biodistribution in Healthy KM Mice and Micro PET/CT Imaging in U87MG Tumor-Bearing Nude Mice of a New 18F-Labeled Cyclic RGD Dimer

Preclinical Micropet Imaging in Tumor-Bearing Nude Mice and Pharmacokinetic Studies of 18F-Alfatide II

Early Response Monitoring Following Radiation Therapy by Using [18F]FDG and [11c]acetate PET in Prostate Cancer Xenograft Model with Metabolomics Corroboration

Monitoring of Tumor Response to Au Nanorod-Indocyanine Green Conjugates Mediated Therapy with Fluorescence Imaging and Positron Emission Tomography

18F‑alfatide Positron Emission Tomography May Predict Anti‑angiogenic Responses

Pretreatment PET/CT imaging of angiogenesis based on 18 F-RGD tracer uptake may predict antiangiogenic response

18F-Labeled Magnetic Nanoparticles for Monitoring Anti-Angiogenic Therapeutic Effects in Breast Cancer Xenografts.

Dual-Tracer Assessment of Dynamic Changes in Reoxygenation and Proliferation Decrease During Fractionated Radiotherapy in Murine Tumors.

Longitudinal Monitoring Of Tumor Antiangiogenic Therapy With Near-Infrared Fluorophore-Labeled Agents Targeted To Integrin Alpha(V)Beta(3) And Vascular Endothelial Growth Factor

Longitudinal monitoring of tumor antiangiogenic therapy with near-infrared fluorophore-labeled agents targeted to integrin α v β 3 and vascular endothelial growth factor

Early therapy monitoring of 125Ⅰ seed interstitial implant in a pancreatic cancer xenograft by 18FFDG Micro-PET/CT

Micro-PET/CT scanning for evaluating early effect of interstitial brachytherapy in treating transplantation tumor of human pancreatic carcinoma in Balb/c-nu mice

18F-Alfatide II and 18F-FDG Dual-Tracer Dynamic PET for Parametric, Early Prediction of Tumor Response to Therapy